Review: Clinical aspects of hereditary DNA Mismatch repair gene mutations

DNA Repair

Volumn 38, Issue , 2016, Pages 155-162

  Sijmons, Rolf H ^a   Hofstra, Robert M W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinic; Constitutional Mismatch Repair Deficiency syndrome; DNA Mismatch repair; Lynch syndrome; MLH1; MSH2; MSH6; PMS2; Review

Indexed keywords

BRAIN TUMOR; CANCER PREVENTION; CANCER RISK; CLINICAL CLASSIFICATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; GENE; GENE MUTATION; GENETIC VARIABILITY; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MORTALITY RATE; PRIORITY JOURNAL; REVIEW; GENETIC PREDISPOSITION; GENETICS; MUTATION;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MICROSATELLITE INSTABILITY; MUTATION;

EID: 84961289272     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2015.11.018     Document Type: Review

References (103)

1. Lynch H.T., Snyder C.L., Shaw T.G., Heinen C.D., Hitchins M.P. Milestones of Lynch syndrome: 1895-2015. Nat. Rev. Cancer 2015, 15(March (3)):181-194. Epub 2015 February 12. 10.1038/nrc3878.
2. Muir E.G., Yates Bell A.J., Barlow K.A. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br. J. Surg. 1967, 54:191-195.
3. Torre D. Multiple sebaceous tumors. Arch. Dermatol. 1968, 98(5):549-551.
4. South C.D., Hampel H., Comeras I., Westman J.A., Frankel W.L., de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J. Natl. Cancer Inst. 2008, 100(February (4)):277-281.
5. Risinger J.I., Barrett J.C., Watson P., Lynch H.T., Boyd J. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 1996, 77(May (9)):1836-1843.
6. ten Broeke S.W., Brohet R.M., Tops C.M., van der Klift H.M., Velthuizen M.E., Bernstein I., Capellá Munar G., Gomez Garcia E., Hoogerbrugge N., Letteboer T.G., Menko F.H., Lindblom A., Mensenkamp A.R., Moller P., van Os T.A., Rahner N., Redeker B.J., Sijmons R.H., Spruijt L., Suerink M., Vos Y.J., Wagner A., Hes F.J., Vasen H.F., Nielsen M., Wijnen J.T. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J. Clin. Oncol. 2015, 33(February (4)):319-325.
7. Win A.K., Lindor N.M., Young J.P., Macrae F.A., Young G.P., Williamson E., Parry S., Goldblatt J., Lipton L., Winship I., Leggett B., Tucker K.M., Giles G.G., Buchanan D.D., Clendenning M., Rosty C., Arnold J., Levine A.J., Haile R.W., Gallinger S., Le Marchand L., Newcomb P.A., Hopper J.L., Jenkins M.A. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J. Natl. Cancer Inst. 2012, 104(September (18)):1363-1372.
8. Engel C., Loeffler M., Steinke V., Rahner N., Holinski-Feder E., Dietmaier W., Schackert H.K., Goergens H., von Knebel Doeberitz M., Goecke T.O., Schmiegel W., Buettner R., Moeslein G., Letteboer T.G., Gómez García E., Hes F.J., Hoogerbrugge N., Menko F.H., van Os T.A., Sijmons R.H., Wagner A., Kluijt I., Propping P., Vasen H.F. Risks of less common cancers in proven mutation carriers with Lynch syndrome. J. Clin. Oncol. 2012, 30(December (35)):4409-4415.
9. Ryan S., Jenkins M.A., Win A.K. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2014, 23(March (3)):437-449.
10. Rosty C., Walsh M.D., Lindor N.M., Thibodeau S.N., Mundt E., Gallinger S., Aronson M., Pollett A., Baron J.A., Pearson S., Clendenning M., Walters R.J., Nagler B.N., Crawford W.J., Young J.P., Winship I., Win A.K., Hopper J.L., Jenkins M.A., Buchanan D.D. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry. Fam. Cancer 2014, 13(December (4)):573-582.
11. Sijmons R., Hofstra R., Hollema H., Mensink R., van der Hout A., Hoekstra H., Kleibeuker J., Molenaar W., Wijnen J., Fodde R., Vasen H., Buys C. Inclusion of malignant fibrous histiocytoma in the tumour spectrum associated with hereditary non-polyposis colorectal cancer. Genes Chromosomes Cancer 2000, 29(December (4)):353-355.
12. Nilbert M., Therkildsen C., Nissen A., Akerman M., Bernstein I. Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. Fam. Cancer 2009, 8(3):209-213.
13. Dunlop M.G., Farrington S.M., Carothers A.D., Wyllie A.H., Sharp L., Burn J., Liu B., Kinzler K.W., Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum. Mol. Genet. 1997, 6(1):105-110.
14. Aarnio M., Sankila R., Pukkala E., Salovaara R., Aaltonen L.A., de la Chapelle A., Peltomäki P., Mecklin J.P., Järvinen H.J. Cancer risk in mutation carriers of DNA-mismatch-repair genes: International journal of cancer. Int. J. Cancer 1999, 81(2):214-218.
15. Vasen H.F., Wijnen J.T., Menko F.H., Kleibeuker J.H., Taal B.G., Griffioen G., Nagengast F.M., Meijers-Heijboer E.H., Bertario L., Varesco L., Bisgaard M.L., Mohr J., Fodde R., Khan P.M. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996, 110(4):1020-1027.
16. Carayol J., Khlat M., Maccario J., Bonaïti-Pellié C. Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated. J. Med. Genet. 2002, 39(5):335-339.
17. Vasen H.F., Stormorken A., Menko F.H., Nagengast F.M., Kleibeuker J.H., Griffioen G., Taal B.G., Moller P., Wijnen J.T. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J. Clin. Oncol. 2001, 19(20):4074-4080.
18. Hendriks Y.M., Wagner A., Morreau H., Menko F., Stormorken A., Quehenberger F., Sandkuijl L., Møller P., Genuardi M., Van Houwelingen H., Tops C., Van Puijenbroek M., Verkuijlen P., Kenter G., Van Mil A., Meijers-Heijboer H., Tan G.B., Breuning M.H., Fodde R., Wijnen J.T., Bröcker-Vriends A.H., Vasen H. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127(1):17-25.
19. Plaschke J., Engel C., Krüger S., Holinski-Feder E., Pagenstecher C., Mangold E., Moeslein G., Schulmann K., Gebert J., von Knebel Doeberitz M., Rüschoff J., Loeffler M., Schackert H.K. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J. Clin. Oncol. 2004, 22(22):4486-4494.
20. Buttin B.M., Powell M.A., Mutch D.G., Babb S.A., Huettner P.C., Edmonston T.B., Herzog T.J., Rader J.S., Gibb R.K., Whelan A.J., Goodfellow P.J. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am. J. Hum. Genet. 2004, 74(6):1262-1269.
21. Hampel H., Stephens J.A., Pukkala E., Sankila R., Aaltonen L.A., Mecklin J.P., de la Chapelle A. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129(2):415-421.
22. Quehenberger F., Vasen H.F., van Houwelingen H.C. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J. Med. Genet. 2005, 42(6):491-496.
23. Barrow E., Alduaij W., Robinson L., Shenton A., Clancy T., Lalloo F., Hill J., Evans D. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin. Genet. 2008.
24. Watson P., Vasen H.F., Mecklin J.P., Bernstein I., Aarnio M., Järvinen H.J., Myrhøj T., Sunde L., Wijnen J.T., Lynch H.T. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int. J. Cancer 2008, 123(2):444-449.
25. Kastrinos F., Mukherjee B., Tayob N., Wang F., Sparr J., Raymond V.M., Bandipalliam P., Stoffel E.M., Gruber S.B., Syngal S. Risk of pancreatic cancer in families with lynch syndrome. JAMA 2009, 302(October (16)):1790-1795.
26. Baglietto L., Lindor N.M., Dowty J.G., White D.M., Wagner A., Gomez G., arcia E.B., Vriends A.H., Dutch Lynch Syndrome Study Group, Cartwright N.R., Barnetson R.A., Farrington S.M., Tenesa A., Hampel H., Buchanan D., Arnold S., Young J., Walsh M.D., Jass J., Macrae F., Antill Y., Winship I.M., Giles G.G., Goldblatt J., Parry S., Suthers G., Leggett B., Butz M., Aronson M., Poynter J.N., Baron J.A., Le Marchand L., Haile R., Gallinger S., Hopper J.L., Potter J., de la Chapelle A., Vasen H.F., Dunlop M.G., Thibodeau S.N., Jenkins M.A. Risks of lynch syndrome cancers for MSH6 mutation carriers. J. Natl. Cancer Inst. 2010, 102(February (3)):193-201.
27. Boilesen A.E., Bisgaard M.L., Bernstein I. Risk of gynecologic cancers in Danish hereditary non- polyposis colorectal cancer families. Acta Obstet. Gynecol. Scand. 2008, 87(11):1129-1135.
28. Bonadona V., et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011, 305(22):2304-2310.
29. Dowty J.G., Win A.K., Buchanan D.D., Lindor N.M., Macrae F.A., Clendenning M., Antill Y.C., Thibodeau S.N., Casey G., Gallinger S., Marchand L.L., Newcomb P.A., Haile R.W., Young G.P., James P.A., Giles G.G., Gunawardena S.R., Leggett B.A., Gattas M., Boussioutas A., Ahnen D.J., Baron J.A., Parry S., Goldblatt J., Young J.P., Hopper J.L., Jenkins M.A. Cancer risks for MLH1 and MSH2 mutation carriers. Hum. Mutat. 2013, 34(March (3)):490-497.
30. Ligtenberg M.J., Kuiper R.P., Chan T.L., Goossens M., Hebeda K.M., Voorendt M., Lee T.Y., Bodmer D., Hoenselaar E., Hendriks-Cornelissen S.J., Tsui W.Y., Kong C.K., Brunner H.G., van Kessel A.G., Yuen S.T., van Krieken J.H., Leung S.Y., Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat. Genet. 2009, 41(January (1)):112-117.
31. Kempers M.J., Kuiper R.P., Ockeloen C.W., Chappuis P.O., Hutter P., Rahner N., Schackert H.K., Steinke V., Holinski-Feder E., Morak M., Kloor M., Büttner R., Verwiel E.T., van Krieken J.H., Nagtegaal I.D., Goossens M., van der Post R.S., Niessen R.C., Sijmons R.H., Kluijt I., Hogervorst F.B., Leter E.M., Gille J.J., Aalfs C.M., Redeker E.J., Hes F.J., Tops C.M., van Nesselrooij B.P., van Gijn M.E., Gómez García E.B., Eccles D.M., Bunyan D.J., Syngal S., Stoffel E.M., Culver J.O., Palomares M.R., Graham T., Velsher L., Papp J., Oláh E., Chan T.L., Leung S.Y., van Kessel A.G., Kiemeney L.A., Hoogerbrugge N., Ligtenberg M.J. Risk of colorectal and endometrial cancers in EPCAM deletion-positive lynch syndrome: a cohort study. Lancet Oncol. 2011, 12(January (1)):49-55.
32. Senter L., Clendenning M., Sotamaa K., Hampel H., Green J., Potter J.D., Lindblom A., Lagerstedt K., Thibodeau S.N., Lindor N.M., Young J., Winship I., Dowty J.G., White D.M., Hopper J.L., Baglietto L., Jenkins M.A., de la Chapelle A. The clinical phenotype of lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008, 135(2):419-428.e1.
33. Brand R.M., Jones D.D., Lynch H.T., Brand R.E., Watson P., Ashwathnayaran R., Roy H.K. Risk of colon cancer in hereditary non-polyposis colorectal cancer patients as predicted by fuzzy modeling: influence of smoking. World J. Gastroenterol. 2006 Jul 28, 12(28):4485-4491.
34. Pande M., Lynch P.M., Hopper J.L., Jenkins M.A., Gallinger S., Haile R.W., LeMarchand L., Lindor N.M., Campbell P.T., Newcomb P.A., Potter J.D., Baron J.A., Frazier M.L., Amos C.I. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. Clin Cancer Res. 2010, 16(February (4)):1331-1339.
35. Winkels R.M., Botma A., Van Duijnhoven F.J., Nagengast F.M., Kleibeuker J.H., Vasen H.F., Kampman E. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. Gastroenterology 2012, 142(February (2)):241-247.
36. Tanakaya K., Furukawa Y., Nakamura Y., Hirata K., Tomita N., Tamura K., Sugano K., Ishioka C., Yoshida T., Ishida H., Watanabe T., Sugihara K., HNPCC registry and genetic testing project of the Japanese Society for Cancer of the Colon and Rectum, Yamaguchi T., Ishikawa H., Matsubara N., Arai M., Moriya Y. Relationship between smoking and multiple colorectal cancers in patients with Japanese Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Jpn. J. Clin. Oncol. 2015, 45(March (3)):307-310.
37. Botma A., Nagengast F.M., Braem M.G., Hendriks J.C., Kleibeuker J.H., Vasen H.F., Kampman E. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. J. Clin. Oncol. Oct 1 2010, 28(October (28)):4346-4353.
38. Botma A., Vasen H.F., van Duijnhoven F.J., Kleibeuker J.H., Nagengast F.M., Kampman E. Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOLynch cohort study. Cancer 2013, 119(February (3)):512-521.
39. Movahedi M., Bishop D.T., Macrae F., Mecklin J.P., Moeslein G., Olschwang S., Eccles D., Evans D.G., Maher E.R., Bertario L., Bisgaard M.L., Dunlop M.G., Ho J.W., Hodgson S.V., Lindblom A., Lubinski J., Morrison P.J., Murday V., Ramesar R.S., Side L., Scott R.J., Thomas H.J., Vasen H.F., Burn J., Mathers J.C. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J. Clin. Oncol. 2015, 58(August). pii: JCO.2014.58.9952. [Epub ahead of print].
40. Talseth-Palmer B.A., Wijnen J.T., Brenne I.S., Jagmohan-Changur S., Barker D., Ashton K.A., Tops C.M., Evans T.J., McPhillips M., Groombridge C., Suchy J., Kurzawski G., Dutch Cancer Genetics Group, Spigelman A., Møller P., Morreau H.M., Van Wezel T., Lubinski J., Vasen H.F., Scott R.J. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int. J. Cancer 2013, 132(April (7)):1556-1564.
41. Seguí N., Guinó E., Pineda M., Navarro M., Bellido F., Lázaro C., Blanco I., Moreno V., Capellá G., Valle L. Longer telomeres are associated with cancer risk in MMR-proficient hereditary non-polyposis colorectal cancer. PLoS One 2014, 9(February (2)):e86063.
42. Church J., McGannon E. Family history of colorectal cancer: how often and how accurately is it recorded?. Dis. Colon Rectum 2000, 43(11):1540-1544.
43. Grover Z.S., Stoffel E.M., Bussone L., Tschoegl E., Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin. Gastroenterol. Hepatol. 2004, 2(9):813-819.
44. Katballe N., Juul S., Christensen M., Ørntoft T.F., Wikman F.P., Laurberg S. Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members. Br. J. Surg. 2001, 88(9):1228-1233.
45. Vasen H.F., Watson P., Mecklin J.P., Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116(6):1453-1456.
46. Umar A., Boland C.R., Terdiman J.P., Syngal S., de la Chapelle A., Rüschoff J., Fishel R., Lindor N.M., Burgart L.J., Hamelin R., Hamilton S.R., Hiatt R.A., Jass J., Lindblom A., Lynch H.T., Peltomaki P., Ramsey S.D., Rodriguez-Bigas M.A., Vasen H.F., Hawk E.T., Barrett J.C., Freedman A.N., Srivastava S. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004, 96(4):261-268.
47. Barnetson R.A., Tenesa A., Farrington S.M., et al. Identification and survival of carriers of mutations in DNA: mismatch repair genes in colon cancer. N. Engl. J. Med. 2006, 354:2751-2763.
48. Chen S., Wang W., Lee S., et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006, 296:1479-1487.
49. Monzon J.G., Cremin C., Armstrong L., Nuk J., Young S., Horsman D.E., Garbutt K., Bajdik C.D., Gill S. Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. Int. J. Cancer 2010 Feb 15, 126(4):930-939.
50. Kastrinos F., Steyerberg E.W., Mercado R., et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011, 140:73-81.e5.
51. Khan O., Blanco A., Conrad P., Gulden C., Moss T.Z., Olopade O.I., Kupfer S.S., Terdiman J. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am. J. Gastroenterol. 2011, 106(October (10)):1822-1827.
52. Kastrinos F., Balmaña J., Syngal S. Prediction models in Lynch syndrome. Fam. Cancer. 2013, 12(June (2)):217-228.
53. Hampel H., Frankel W.L., Martin E., Arnold M., Khanduja K., Kuebler P., Nakagawa H., Sotamaa K., Prior T.W., Westman J., Panescu J., Fix D., Lockman J., Comeras I., de la Chapelle A. Screening for the Lynch syndrome hereditary nonpolyposis colorectal cancer). N. Engl. J. Med. 2005, 352(May (18)):1851-1860.
54. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009, 11(January (1)):35-41.
55. Ladabaum U., Wang G., Terdiman J., Blanco A., Kuppermann M., Boland C.R., Ford J., Elkin E., Phillips K.A. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann. Intern. Med. 2011, 155(July (2)):69-79.
56. Barzi A., Sadeghi S., Kattan M.W., Meropol N.J. Comparative effectiveness of screening strategies for Lynch syndrome. J. Natl. Cancer Inst. 2015, 107(March (4)).
57. Snowsill T., Huxley N., Hoyle M., Jones-Hughes T., Coelho H., Cooper C., Frayling I., Hyde C. A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer 2015, 15(April (1)):313. [Epub ahead of print].
58. Snowsill T., Huxley N., Hoyle M., Jones-Hughes T., Coelho H., Cooper C., Frayling I., Hyde C. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol. Assess. 2014, 18(September (58)):1-406. 10.3310/hta18580.
59. Ferguson S.E., Aronson M., Pollett A., Eiriksson L.R., Oza A.M., Gallinger S., Lerner-Ellis J., Alvandi Z., Bernardini M.Q., MacKay H.J., Mojtahedi G., Tone A.A., Massey C., Clarke B.A. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 2014, 120(December (24)):3932-3939.
60. Rabban J.T., Calkins S.M., Karnezis A.N., Grenert J.P., Blanco A., Crawford B., Chen L.M. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Am. J. Surg. Pathol. 2014 Jun, 38(6):793-800.
61. Bruegl A.S., Djordjevic B., Batte B., Daniels M., Fellman B., Urbauer D., Luthra R., Sun C., Lu K.H., Broaddus R.R. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev. Res. (Phila.) 2014, 7(July (7)):686-697.
62. Sugawara T., Sato N., Shimizu D., Sato T., Makino K., Kito M., Tamura D., Kato A., Terada Y. Efficient screening strategy for Lynch syndrome in Japanese endometrial cancer. Tohoku J. Exp. Med. 2015, 235(2):117-125.
63. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., Meltzer S.J., Rodriguez-Bigas M.A., Fodde R., Ranzani G.N., Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 Nov 15, 58(22):5248-5257.
64. Ferreira A.M., Westers H., Sousa S., Wu Y., Niessen R.C., Olderode-Berends M., van der Sluis T., Reuvekamp P.T., Seruca R., Kleibeuker J.H., Hollema H., Sijmons R.H., Hofstra R.M. Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients. J. Pathol. 2009, 219(September (1)):96-102.
65. Hofstra R.M., Spurdle A.B., Eccles D., Foulkes W.D., de W., ind N., Hoogerbrugge N., Hogervorst F.B., IARC Unclassified Genetic Variants Working Group Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum. Mutat. 2008, 29(November (11)):1292-1303.
66. Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., Lönnqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., Gerdes A.M., Peltomäki P., Kohonen-Ccorish M., Mangold E., Macrae F., Greenblatt M., de la Chapelle A., Nyström M. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology. Aug 2005, 129(August (2)):537-549.
67. Cunningham J.M., Christensen E.R., Tester D.J., Kim C.Y., Roche P.C., Burgart L.J., Thibodeau S.N. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998, 58(August (15)):3455-3460.
68. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., Markowitz S., Willson J.K., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., Vogelstein B., Kunkel T.A., Baylin S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(June (12)):6870-6875.
69. Jass J.R. Heredity and DNA methylation in colorectal cancer. Gut 2007, 56(January (1)):154-155.
70. Hitchins M.P., Ward R.L. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J. Med. Genet. 2009, 46(December (12)):793-802.
71. Rahner N., Friedrichs N., Steinke V., Aretz S., Friedl W., Buettner R., Mangold E., Propping P., Walldorf C. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J. Pathol. 2008 Jan, 214(January (1)):10-16.
72. Chen D., Huang J.F., Liu K., Zhang L.Q., Yang Z., Chuai Z.R., Wang Y.X., Shi D.C., Huang Q., Fu W.L. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014, 9:e90607.
73. Hemminki A., Peltomäki P., Mecklin J.P., Järvinen H., Salovaara R., Nyström-Lahti M., de la Chapelle A., Aaltonen L.A. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat. Genet. 1994, 8(December (4)):405-410.
74. Haraldsdottir S., Hampel H., Tomsic J., Frankel W.L., Pearlman R., de la Chapelle A., Pritchard C.C. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014, 147(December (6)):1308-1316. e1.
75. Mensenkamp A.R., Vogelaar I.P., Zelst-Stams W.A., Goossens M., Ouchene H., Hendriks-Cornelissen S.J., Kwint M.P., Hoogerbrugge N., Nagtegaal I.D., Ligtenberg M.J. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146(March (3)):643-646. e8. 10.1053/j.gastro.2013.12.002.
76. Geurts-Giele W.R., Leenen C.H., Dubbink H.J., Meijssen I.C., Post E., Sleddens H.F., Kuipers E.J., Goverde A., van, den O., uweland A.M., van L., ier M.G., Steyerberg E.W., van L., eerdam M.E., Wagner A., Dinjens W.N. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. J Pathol. Dec 2014, 234(4):548-559.
77. Sijmons R.H., Greenblatt M.S., Genuardi M. Gene variants of unknown clinical significance in Lynch syndrome. An introduction for clinicians. Fam. Cancer 2013, 12(June (2)):181-187.
78. Heinen C.D. Mismatch repair defects and Lynch syndrome: the role of the basic scientist in the battle against cancer. DNA Repair 2016, (in this issue).
79. Pena-Diaz J., Rasmussen L.J. Approaches to diagnose DNA mismatch repair gene defects in cancer. DNA Repair 2016, (in this issue).
80. Thompson B.A., Spurdle A.B., Plazzer J.P., Greenblatt M.S., Akagi K., Al-Mulla F., Bapat B., Bernstein I., Capellá G., den Dunnen J.T., du Sart D., Fabre A., Farrell M.P., Farrington S.M., Frayling I.M., Frebourg T., Goldgar D.E., Heinen C.D., Holinski-Feder E., Kohonen-Corish M., Robinson K.L., Leung S.Y., Martins A., Moller P., Morak M., Nystrom M., Peltomaki P., Pineda M., Qi M., Ramesar R., Rasmussen L.J., Royer-Pokora B., Scott R.J., Sijmons R., Tavtigian S.V., Tops C.M., Weber T., Wijnen J., Woods M.O., Macrae F., Genuardi M., InSiGHT Application of a 5-tiered scheme for standardized classification of 2360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. Feb 2014, 46(February (2)):107-115.
81. Drost M., Lützen A., van H., ees S., Ferreira D., Calléja F., Zonneveld J.B., Nielsen F.C., Rasmussen L.J., de Wind N. Genetic screens to identify pathogenic gene variants in the common cancer predisposition Lynch syndrome. Proc. Natl. Acad. Sci. U. .S A. 2013, 110(June (23)):9403-9408.
82. Vasen H.F., Blanco I., Aktan-Collan K., Gopie J.P., Alonso A., Aretz S., Bernstein I., Bertario L., Burn J., Capella G., Colas C., Engel C., Frayling I.M., Genuardi M., Heinimann K., Hes F.J., Hodgson S.V., Karagiannis J.A., Lalloo F., Lindblom A., Mecklin J.P., Møller P., Myrhoj T., Nagengast F.M., Parc Y., Ponz de Leon M., Renkonen-Sinisalo, Sampson J.R., Stormorken A., Sijmons R.H., Tejpar S., Thomas H.J., Rahner N., Wijnen J.T., Järvinen H.J., G Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62(June (6)):812-823.
83. Giardiello F.M., Allen J.I., Axilbund J.E., Boland C.R., Burke C.A., Burt R.W., Church J.M., Dominitz J.A., Johnson D.A., Kaltenbach T., Levin T.R., Lieberman D.A., Robertson D.J., Syngal S., Rex D.K. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am. J. Gastroenterol. 2014, 109(August (8)):1159-1179.
84. Vasen H.F., Blanco I., Aktan-Collan K., Gopie J.P., Alonso A., Aretz S., Bernstein I., Bertario L., Burn J., Capella G., Colas C., Engel C., Frayling I.M., Genuardi M., Heinimann K., Hes F.J., Hodgson S.V., Karagiannis J.A., Lalloo F., Lindblom A., Mecklin J.P., Møller P., Myrhoj T., Nagengast F.M., Parc Y., Ponz de Leon M., Renkonen-Sinisalo L., Sampson J.R., Stormorken A., Sijmons R.H., Tejpar S., Thomas H.J., Rahner N., Wijnen J.T., Järvinen H.J., Möslein G. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62(June (6)):812-823.
85. Lindor N.M., Petersen G.M., Hadley D.W., Kinney A.Y., Miesfeldt S., Lu K.H., Lynch P., Burke W., Press N. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006, 296(September (12)):1507-1517.
86. Syngal S., Brand R.E., Church J.M., Giardiello F.M., Hampel H.L., Burt R.W., American College of Gastroenterology ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am. J. Gastroenterol. Feb 2015, 110(February (2)):223-262.
87. Järvinen H.J., Aarnio M., Mustonen H., Aktan-Collan K., Aaltonen L.A., Peltomäki P., De La Chapelle A., Mecklin J.P. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118(May (5)):829-834.
88. de Vos tot Nederveen Cappel W.H., Nagengast F.M., Griffioen G., Menko F.H., Taal B.G., Kleibeuker J.H., Vasen H.F. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis. Colon Rectum 2002, 45(December (12)):1588-1594.
89. Stupart D.A., Goldberg P.A., Algar U., Ramesar R. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis. 2009, 11(February (2)):126-130.
90. Engel C., Rahner N., Schulmann K., Holinski-Feder E., Goecke T.O., Schackert H.K., Kloor M., Steinke V., Vogelsang H., Möslein G., Görgens H., Dechant S., von Knebel Doeberitz M., Rüschoff J., Friedrichs N., Büttner R., Loeffler M., Propping P., Schmiegel W., German HNPCC Consortium Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin. Gastroenterol. Hepatol. 2010, 8(February (2)):174-182.
91. Bernstein I.T., Myrhøj T. Surveillance for urinary tract cancer in Lynch syndrome. Fam. Cancer 2013, 12(June (2)):279-284.
92. Koornstra J.J. Small bowel endoscopy in familial adenomatous polyposis and Lynch syndrome. Best Pract. Res. Clin. Gastroenterol. 2012, 26(June (3)):359-368.
93. Koornstra J.J., Mourits M.J., Sijmons R.H., Leliveld A.M., Hollema H., Kleibeuker J.H. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009 Apr, 10(4):400-408.
94. Parry S., Win A.K., Parry B., Macrae F.A., Gurrin L.C., Church J.M., Baron J.A., Giles G.G., Leggett B.A., Winship I., Lipton L., Young G.P., Young J.P., Lodge C.J., Southey M.C., Newcomb P.A., Le Marchand L., Haile R.W., Lindor N.M., Gallinger S., Hopper J.L., Jenkins M.A. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011, 60(July (7)):950-957.
95. Haanstra J.F., de Vos Tot Nederveen Cappel W.H., Gopie J.P., Vecht J., Vanhoutvin S.A., Cats A., van der Zaag-Loonen H.J., Langers A.M., Bergmann J.H., van de Meeberg P.C., Dekker E., Kleibeuker J.H., Vasen H.F., Nagengast F.M., van Duijvendijk P. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. Dis. Colon Rectum 2012 Jun, 55(June (6)):653-659.
96. Burn J., Gerdes A.M., Macrae F., Mecklin J.P., Moeslein G., Olschwang S., Eccles D., Evans D.G., Maher E.R., Bertario L., Bisgaard M.L., Dunlop M.G., Ho J.W., Hodgson S.V., Lindblom A., Lubinski J., Morrison P.J., Murday V., Ramesar R., Side L., Scott R.J., Thomas H.J., Vasen H.F., Barker G., Crawford G., Elliott F., Movahedi M., Pylvanainen K., Wijnen J.T., Fodde R., Lynch H.T., Mathers J.C., Bishop D.T., CAPP2 Investigators Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378(December (9809)):2081-2087.
97. Campregher C., Honeder C., Chung H., Carethers J.M., Gasche C. Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin. Cancer Res. 2010 Mar 15, 16(6):1950-1956.
98. C. Gasche, MesaCapp: Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome. <>. http://www.transcanfp7.eu/transcan/file.php/1/Calls/JTC-2012/Selected_projects/CANCER12-MesaCapp.pdf.
99. Vasen H.F., Ghorbanoghli Z., Bourdeaut F., Cabaret O., Caron O., Duval A., Entz-Werle N., Goldberg Y., Ilencikova D., Kratz C.P., Lavoine N., Loeffen J., Menko F.H., Muleris M., Sebille G., Colas C., Burkhardt B., Brugieres L., Wimmer K. EU-Consortium Care for CMMR-D (C4CMMR-D). Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium Care for CMMR-D (C4CMMR-D). J. Med. Genet. 2014, 51(May (5)):283-293.
100. Herkert J.C., Niessen R.C., Olderode-Berends M.J., Veenstra-Knol H.E., Vos Y.J., van der Klift H.M., Scheenstra R., Tops C.M., Karrenbeld A., Peters F.T., Hofstra R.M., Kleibeuker J.H., Sijmons R.H. Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 mutations: case series, review and follow-up guidelines. Eur. J. Cancer 2011, 47(May (7)):965-982.
101. Bakry D., Aronson M., Durno C., Rimawi H., Farah R., Alharbi Q.K., Alharbi M., Shamvil A., Ben-Shachar S., Mistry M., Constantini S., Dvir R., Qaddoumi I., Gallinger S., Lerner-Ellis J., Pollett A., Stephens D., Kelies S., Chao E., Malkin D., Bouffet E., Hawkins C., Tabori U. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur. J. Cancer. Mar 2014, 50(March (5)):987-996.
102. Shlien A., Campbell B.B., de Borja R., Alexandrov L.B., Merico D., Wedge D., Van Loo P., Tarpey P.S., Coupland P., Behjati S., Pollett A., Lipman T., Heidari A., Deshmukh S., Avitzur N., Meier B., Gerstung M., Hong Y., Merino D.M., Ramakrishna M., Remke M., Arnold R., Panigrahi G.B., Thakkar N.P., Hodel K.P., Henninger E.E., Göksenin A.Y., Bakry D., Charames G.S., Druker H., Lerner-Ellis J., Mistry M., Dvir R., Grant R., Elhasid R., Farah R., Taylor G.P., Nathan P.C., Alexander S., Ben-Shachar S., Ling S.C., Gallinger S., Constantini S., Dirks P., Huang A., Scherer S.W., Grundy R.G., Durno C., Aronson M., Gartner A., Meyn M.S., Taylor M.D., Pursell Z.F., Pearson C.E., Malkin D., Futreal P.A., Stratton M.R., Bouffet E., Hawkins C., Campbell P.J., Tabori U., Biallelic Mismatch Repair Deficiency Consortium Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 2015, 47(March (3)):257-262.
103. Wimmer K., Kratz C.P., Vasen H.F., Caron O., Colas C., Entz-Werle N., Gerdes A.M., Goldberg Y., Ilencikova D., Muleris M., Duval A., Lavoine N., Ruiz-Ponte C., Slavc I., Burkhardt B., Brugieres L. EU-Consortium Care for CMMRD (C4CMMRD). Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J. Med .Genet. 2014, 51(June (6)):355-365.